Sanofi reaffirms ambition to deliver >€10bn in annual vaccines sales by 2030
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
This product will be manufactured at Lupin's Pithampur facility in India
Sun Pharma will have exclusive rights to commercialise Nidlegy for indications of skin cancers in the territories of Europe, Australia and New Zealand. Philogen will complete pivotal clinical trials for the product in Europe
Glucon-D, Sugar Free, EverYuth Scrub, Peel Off Face Mask and Nycil maintained their leadership positions in their respective categories as on March 2023
Proposed divestiture of BioPharma Solutions (BPS) further streamlines Baxter’s strategic focus and represents an important milestone in its ongoing business transformation
The acquisition of Medisol is part of Lupin's strategy to expand its presence in the EU
Ayurveda OPD will be established in 10 ECHS Polyclinic/Dispensaries in various regions of India to cover all ECHS members on a voluntary basis
Operating EBITDA grew by 82.7 % to Rs. 14.4 crore, EBITDA margin at 23.9%, and Profit After Tax (PAT) grew by 47.1% to Rs. 7.8 crore
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
Subscribe To Our Newsletter & Stay Updated